{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T12:43:47Z","timestamp":1786538627418,"version":"build-2736575974"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100011010","name":"European SocieTy for Radiotherapy and Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008467","name":"Canadian Association of Radiation Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008467","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.radonc.2025.111199","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T22:17:04Z","timestamp":1760048224000},"page":"111199","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Ultra-hypofractionated radiotherapy combined with HDR brachytherapy: An optimized treatment"],"prefix":"10.1016","volume":"214","author":[{"given":"I.","family":"Sidib\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5739-8417","authenticated-orcid":false,"given":"M.M.","family":"Beaudry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3086-2010","authenticated-orcid":false,"given":"D.","family":"Carignan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.","family":"Froment","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3661-9767","authenticated-orcid":false,"given":"F.","family":"Bachand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7201-9400","authenticated-orcid":false,"given":"E.","family":"Vigneault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Magnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Aubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Morrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2138-2063","authenticated-orcid":false,"given":"E.","family":"Poulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Lacroix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1037-4658","authenticated-orcid":false,"given":"M.C.","family":"Lavall\u00e9e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0429-6366","authenticated-orcid":false,"given":"L.","family":"Beaulieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4214-9148","authenticated-orcid":false,"given":"A.G.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2025.111199_b0005","unstructured":"Cancer Today n.d. https:\/\/gco.iarc.who.int\/today\/ (accessed September 20, 2024)."},{"key":"10.1016\/j.radonc.2025.111199_b0010","first-page":"583","article-title":"NCCN guidelines updates: management of prostate cancer","volume":"17","author":"Mohler","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.radonc.2025.111199_b0015","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1001\/jama.2018.0587","article-title":"Radical prostatectomy, external beam radiotherapy, or external beam radiotherapy with brachytherapy boost and disease progression and mortality in patients with Gleason score 9-10 prostate cancer","volume":"319","author":"Kishan","year":"2018","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.radonc.2025.111199_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109632","article-title":"Brachytherapy boost improves survival and decreases risk of developing distant metastases compared to external beam radiotherapy alone in intermediate and high risk group prostate cancer patients","volume":"183","author":"Miszczyk","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111199_b0025","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1200\/JCO.20.02873","article-title":"Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the FLAME randomized phase III trial","volume":"39","author":"Kerkmeijer","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2025.111199_b0030","doi-asserted-by":"crossref","first-page":"5596","DOI":"10.1002\/cncr.24558","article-title":"Radiation dose escalation for localized prostate cancer: intensity-modulated radiotherapy versus permanent transperineal brachytherapy","volume":"115","author":"Wong","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2025.111199_b0035","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ijrobp.2016.11.026","volume":"98","author":"Morris","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111199_b0040","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.radonc.2021.12.047","article-title":"GEC-ESTRO ACROP prostate brachytherapy guidelines","volume":"167","author":"Henry","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111199_b0045","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/S0360-3016(01)02664-5","article-title":"Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha\/beta ratio), similar to late-responding normal tissue","volume":"52","author":"Brenner","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111199_b0050","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/S1470-2045(22)00517-4","article-title":"Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial","volume":"23","author":"Tree","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2025.111199_b0055","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.brachy.2021.08.006","article-title":"Early outcomes of high-dose-rate brachytherapy combined with ultra-hypofractionated radiation in higher-risk prostate cancer","volume":"20","author":"Gorovets","year":"2021","journal-title":"Brachytherapy"},{"key":"10.1016\/j.radonc.2025.111199_b0060","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.ijrobp.2020.05.032","article-title":"Low-dose-rate brachytherapy combined with ultrahypofractionated radiation therapy for clinically localized, intermediate-risk prostate cancer: results from a prospective trial","volume":"108","author":"Kollmeier","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111199_b0065","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.brachy.2022.04.006","article-title":"Combined brachytherapy and ultra-hypofractionated radiotherapy for intermediate-risk prostate cancer: Comparison of toxicity outcomes using a high-dose-rate (HDR) versus low-dose-rate (LDR) brachytherapy boost","volume":"21","author":"Kollmeier","year":"2022","journal-title":"Brachytherapy"},{"key":"10.1016\/j.radonc.2025.111199_b0070","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.ijrobp.2023.11.058","article-title":"Is ultrahypofractionated whole pelvis radiation therapy (WPRT) as well tolerated as conventionally fractionated WPRT in patients with prostate cancer? Early results from the HOPE trial","volume":"119","author":"Mendez","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111199_b0075","article-title":"Comparison of four-year toxicities and local control of ultra-hypofractionated vs moderate-hypofractionated image guided prostate radiation with HDR brachytherapy boost: a phase I-II single institution trial","volume":"40","author":"Beaudry","year":"2023","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.radonc.2025.111199_b0080","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.clon.2018.05.007","article-title":"Randomised phase II feasibility trial of image-guided external beam radiotherapy with or without high dose rate brachytherapy boost in men with intermediate-risk prostate cancer (CCTG PR15\/NCT01982786)","volume":"30","author":"Vigneault","year":"2018","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.radonc.2025.111199_b0085","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.ijrobp.2008.05.003","article-title":"An eight-year experience of HDR brachytherapy boost for localized prostate cancer: biopsy and PSA outcome","volume":"73","author":"Bachand","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111199_b0090","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO phoenix consensus conference","volume":"65","author":"Roach","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111199_b0095","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.radonc.2020.04.038","article-title":"A biochemical definition of cure after brachytherapy for prostate cancer","volume":"149","author":"Crook","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111199_b0100","doi-asserted-by":"crossref","first-page":"404","DOI":"10.5489\/cuaj.4428","article-title":"Validation of the French-Canadian version of the expanded prostate cancer index composite (EPIC) in a French-Canadian population","volume":"11","author":"Vigneault","year":"2017","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.radonc.2025.111199_b0105","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial","volume":"394","author":"Widmark","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2025.111199_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.brachy.2024.12.005","article-title":"HDR brachytherapy combined with external beam radiotherapy for unfavorable localized prostate cancer: a single center experience from inception to standard of care","author":"Yeung","year":"2025","journal-title":"Brachytherapy"},{"key":"10.1016\/j.radonc.2025.111199_b0115","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.brachy.2020.07.011","article-title":"Real-world dosimetric comparison between CyberKnife SBRT and HDR brachytherapy for the treatment of prostate cancer","volume":"20","author":"Chatzikonstantinou","year":"2021","journal-title":"Brachytherapy"},{"key":"10.1016\/j.radonc.2025.111199_b0120","article-title":"Treatment planning comparison of high-dose-rate brachytherapy vs. robotic and conventional stereotactic body radiotherapy for ultrahypofractionated treatment of prostate cancer","volume":"26","author":"Yoshioka","year":"2023","journal-title":"Phys Imaging Radiat Oncol"},{"key":"10.1016\/j.radonc.2025.111199_b0125","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.radonc.2021.05.024","article-title":"Stereotactic pelvic radiotherapy with HDR boost for dose escalation in intermediate and high-risk prostate cancer (SPARE): efficacy, toxicity and quality of life","volume":"161","author":"Musunuru","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111199_b0130","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.brachy.2020.02.008","article-title":"A phase IB clinical trial of 15 Gy HDR brachytherapy followed by hypofractionated\/SBRT in the management of intermediate-risk prostate cancer","volume":"19","author":"Den","year":"2020","journal-title":"Brachytherapy"},{"key":"10.1016\/j.radonc.2025.111199_b0135","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.ijrobp.2022.11.005","article-title":"An updated analysis of the survival endpoints of ASCENDE-RT","volume":"115","author":"Oh","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111199_b0140","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.radonc.2017.06.012","article-title":"High-dose-rate brachytherapy boost for prostate cancer treatment: different combinations of hypofractionated regimens and clinical outcomes","volume":"124","author":"Vigneault","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111199_b0145","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ijrobp.2024.12.018","article-title":"Pelvic regional control with 25 Gy in 5 fractions in stereotactic radiation therapy for high-risk prostate cancer: pooled prospective outcomes from the SHARP consortium","volume":"122","author":"Murthy","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111199_b0150","doi-asserted-by":"crossref","first-page":"S1992","DOI":"10.1016\/S0167-8140(25)00935-1","article-title":"2249 Pelvic ultra-hypofractionated vs conventionally fractionated IMRT with HDR brachytherapy boost in prostate cancer: PCS-XI trial interim (NCT05820633)","volume":"206","author":"Fabi","year":"2025","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111199_b0155","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.clon.2021.12.006","article-title":"Ultrahypofractionated radiotherapy for localised prostate cancer: how far can we go?","volume":"34","author":"Corkum","year":"2022","journal-title":"Clin Oncol (R Coll Radiol)"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016781402505203X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016781402505203X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T12:22:55Z","timestamp":1786537375000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016781402505203X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":31,"alternative-id":["S016781402505203X"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2025.111199","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ultra-hypofractionated radiotherapy combined with HDR brachytherapy: An optimized treatment","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2025.111199","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111199"}}